# Efficacy and Safety of Βeta-adrenoceptor Inverse Agonist and Biased Ligand, Nadolol, In Smoking Cessation of Patients With Chronic Cough With or Without Airflow Obstruction

> **NCT01825122** · PHASE2 · COMPLETED · sponsor: **Invion, Inc.** · enrollment: 155 (actual)

## Conditions studied

- Smoking Cessation

## Interventions

- **DRUG:** Nadolol
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01825122
- **Lead sponsor:** Invion, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2015-06
- **Final completion:** 2015-08
- **Target enrollment:** 155 (ACTUAL)
- **Last updated:** 2017-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01825122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01825122, "Efficacy and Safety of Βeta-adrenoceptor Inverse Agonist and Biased Ligand, Nadolol, In Smoking Cessation of Patients With Chronic Cough With or Without Airflow Obstruction". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01825122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*